146 related articles for article (PubMed ID: 26616000)
1. Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma.
Michishita M; Ohtsuka A; Nakahira R; Tajima T; Nakagawa T; Sasaki N; Arai T; Takahashi K
J Vet Med Sci; 2016 May; 78(4):685-9. PubMed ID: 26616000
[TBL] [Abstract][Full Text] [Related]
2. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas.
Millanta F; Lazzeri G; Vannozzi I; Viacava P; Poli A
Vet Pathol; 2002 Nov; 39(6):690-6. PubMed ID: 12450199
[TBL] [Abstract][Full Text] [Related]
3. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops.
Millanta F; Silvestri G; Vaselli C; Citi S; Pisani G; Lorenzi D; Poli A
Res Vet Sci; 2006 Dec; 81(3):350-7. PubMed ID: 16556453
[TBL] [Abstract][Full Text] [Related]
4. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma.
Michishita M; Uto T; Nakazawa R; Yoshimura H; Ogihara K; Naya Y; Tajima T; Azakami D; Kishikawa S; Arai T; Takahashi K
J Pharmacol Sci; 2013; 121(4):339-42. PubMed ID: 23514785
[TBL] [Abstract][Full Text] [Related]
6. Selenium Induces an Anti-tumor Effect Via Inhibiting Intratumoral Angiogenesis in a Mouse Model of Transplanted Canine Mammary Tumor Cells.
Li W; Guo M; Liu Y; Mu W; Deng G; Li C; Qiu C
Biol Trace Elem Res; 2016 Jun; 171(2):371-379. PubMed ID: 26507439
[TBL] [Abstract][Full Text] [Related]
7. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
9. Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.
Islam MS; Matsumoto M; Hidaka R; Miyoshi N; Yasuda N
Vet J; 2012 Jun; 192(3):338-44. PubMed ID: 22154426
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
11. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
12. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
13. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
14. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.
Wentink MQ; Hackeng TM; Tabruyn SP; Puijk WC; Schwamborn K; Altschuh D; Meloen RH; Schuurman T; Griffioen AW; Timmerman P
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12532-12537. PubMed ID: 27791128
[TBL] [Abstract][Full Text] [Related]
15. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
[TBL] [Abstract][Full Text] [Related]
19. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
[TBL] [Abstract][Full Text] [Related]
20. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
